Xu MX, Tan J, Ge CX, Dong W, Zhang LT, Zhu LC, Zhao JJ, Wang LY, Liu J, Wei H, Sun Y, Dai XL, Kuang Q, Li YL, Li H, Liu JY, Zou L, Liang RR, Zhang CF, Xu J, Wang BC

As a global health threat, NASH has been confirmed to be a chronic progressive liver disease that is strongly associated with obesity. However, no approved drugs or efficient therapeutic strategies are valid, mainly because its complicated pathological processes is underestimated.We identified the RING-type E3 ubiquitin transferase-tripartite motif-containing protein 31 (TRIM31), ...

Read More

a member of the E3 ubiquitin ligases family, as an efficient endogenous inhibitor of transforming growth factor-beta-activated kinase 1 (mitogen-activated protein kinase kinase kinase 7; MAP3K7), and we further confirmed that TRIM31 is an MAP3K7-interacting protein and promotes MAP3K7 degradation by enhancing ubiquitination of K48 linkage in hepatocytes. Hepatocyte-specific Trim31 deletion blocks hepatic metabolism homeostasis, concomitant with glucose metabolic syndrome, lipid accumulation, up-regulated inflammation, and dramatically facilitates NASH progression. Inversely, transgenic overexpression, lentivirus, or adeno-associated virus-mediated Trim31 gene therapy restrain NASH in three dietary mice models. Mechanistically, in response to metabolic insults, TRIM31 interacts with MAP3K7 and conjugates K48-linked ubiquitination chains to promote MAP3K7 degradation, thus blocking MAP3K7 abundance and its downstream signaling cascade activation in hepatocytes.TRIM31 may serve as a promising therapeutic target for NASH treatment and associated metabolic disorders.

Date: Apr. 16, 2022

View in: Pubmed Google Scholar

237397